Loading the records…
Loading the records…
The HELP Copays Act (HR6423) is an early-stage bill that would ban accumulator adjustment programs, forcing insurers to count manufacturer copay assistance toward patient deductibles. This increases insurer drug cost liability, creating a bearish signal for major health insurers like UnitedHealth, Cigna, and Humana. The bill is in early committee stage with no near-term market impact.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The HELP Copays Act is a regulatory risk for commercial health insurers. If passed, it would increase insurers' drug cost liability by forcing them to count manufacturer copay assistance toward patient deductibles. This directly affects UnitedHealth, Cigna ($CI), and Humana ($HUM), which have large commercial plan membership and currently use accumulator programs. The bill is in early committee stage, so no immediate market reaction is warranted. Investors should monitor committee markups and hearings for signs of momentum. The companion bill S864 having hearings in the Senate HELP Committee is a positive signal for passage probability, but the bill remains early-stage.
On December 4, 2025, Representative Kean (R-NJ) introduced the HELP Copays Act (HR6423) in the House. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It has 52 cosponsors and an identical companion bill (S864) in the Senate, which has had hearings in the HELP Committee. The bill is in early legislative stages and has not been marked up or voted on.
The bill does not authorize or appropriate any federal funding. It is a regulatory mandate that would change how health insurers treat manufacturer copay assistance. Currently, many insurers use accumulator adjustment programs that exclude manufacturer copay coupons from counting toward patient deductibles and out-of-pocket maximums. This bill would prohibit that practice, requiring insurers to count all copay assistance toward cost-sharing limits. The mechanism is a statutory prohibition on accumulator programs, enforced through ERISA and PHSA requirements.
Structural winners are pharmaceutical companies and patients who benefit from copay assistance programs being more effective. Losers are health insurers who lose the cost-control mechanism of accumulator programs. The primary bearish impact is on commercial health insurers with large employer-group and individual plan membership: UnitedHealth Group, Cigna ($CI), and Humana ($HUM). These insurers currently use accumulator programs to limit their drug cost exposure when manufacturers provide copay coupons for high-cost brand drugs. Banning accumulator programs means insurers cover a larger share of drug costs once patients hit their deductibles faster.
No real market data is provided for stock prices. The legislative timeline is early: the bill has been referred to two committees and has a companion bill with hearings in the Senate. The 52 cosponsors indicate some bipartisan support, but the bill has not advanced to markup or floor votes. The 119th Congress (2025-2027) has two years remaining, so the bill could progress but faces significant opposition from the insurance industry.
Timeline: The next steps are committee hearings and markups in both the House Energy and Commerce and Ways and Means Committees, and the Senate HELP Committee. If the bill passes both chambers and is signed into law, insurers would need to adjust their plan designs and pricing for the next plan year. Given the early stage and insurance industry opposition, passage is uncertain and likely not imminent.
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
Premium Transparency Act
Competitive Health Insurance Reform Act of 2020
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →